STOCK TITAN
  1. Home
  2. News
  3. PHVS

Pharvaris NV - PHVS STOCK NEWS

Welcome to our dedicated news page for Pharvaris NV (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharvaris NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharvaris NV's position in the market.

News
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) reports strong financial results for Q4 and year-end 2023, with cash reserves of €391 million. The company is progressing well with the global Phase 3 clinical development plans for deucrictibant for HAE attacks. Recent achievements include the lifting of the clinical hold by the FDA and the receipt of the UK Innovation Passport for deucrictibant. The executive team has been bolstered with new hires, and upcoming investor presentations are scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
earnings
-
News
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) appoints David Nassif, J.D., as Chief Financial Officer to enhance financial strategy and operations, leveraging his 30 years of experience in financial management and strategic planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
management
-
News
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announced the acceptance of two abstracts for presentation at the CIIC Spring 2024 Conference regarding their oral bradykinin B2 receptor antagonists for hereditary angioedema attacks. The presentations will focus on early-onset response and efficacy/safety of Deucrictibant in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences clinical trial
News
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
Rhea-AI Summary
Pharvaris initiates Phase 3 clinical trial RAPIDe-3 for HAE treatment with deucrictibant. The trial aims to assess efficacy and safety, presenting potential as a best-in-class therapy. The company showcases study designs and quality-of-life data at recent congresses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.34%
Tags
clinical trial
-
News
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
Rhea-AI Summary
Pharvaris (PHVS) announces the acceptance of abstracts for presentation at two upcoming congresses, showcasing the efficacy and safety of their oral bradykinin B2 receptor antagonists in treating hereditary angioedema attacks. The presentations will cover trial designs, results, and patient outcomes, highlighting the potential of their innovative treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
conferences clinical trial
-
News
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
Rhea-AI Summary
Pharvaris (PHVS) to participate in Leerink Global Biopharma Conference 2024 to discuss oral bradykinin B2 receptor antagonists for hereditary angioedema treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
News
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Rhea-AI Summary
Pharvaris (PHVS) announces significant reduction in HAE attack rate with deucrictibant treatment. The CHAPTER-1 Phase 2 trial shows an 84.5% reduction in monthly attack rate with deucrictibant compared to placebo. The treatment is well-tolerated with mild adverse events. The results support the development of deucrictibant as a potential option to treat and prevent HAE attacks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
clinical trial
-
News
Pharvaris Announces Extraordinary Meeting of Shareholders
Rhea-AI Summary
Pharvaris (PHVS) schedules an extraordinary general meeting of shareholders on March 6, 2024, to discuss key developments in their clinical-stage oral bradykinin B2 receptor antagonist for hereditary angioedema treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
News
Pharvaris to Present at the WSAAI Annual Meeting 2024
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) has announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024. The abstracts will focus on the efficacy and safety of their oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema attacks. The presentation will be held at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii, on February 4-8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences
News
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Rhea-AI Summary
Pharvaris (PHVS) announced that the FDA has lifted the clinical hold on the Investigational New Drug application for deucrictibant for the prophylactic treatment of hereditary angioedema attacks. This enables the company to progress the global development of deucrictibant for long-term prophylaxis and to resume the open-label portion of their Phase 2 proof-of-concept study in the U.S. The company also plans to request an End-of-Phase 2 meeting with the FDA to align on key elements of the anticipated global Phase 3 study of deucrictibant extended-release tablets for the prophylactic treatment of HAE attacks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
none
Stock PHVS logo
Pharvaris NV

Nasdaq:PHVS

PHVS Rankings

#2256 Ranked by Market Cap
#18 Ranked by Stock Gains
N/A Ranked by Dividends

PHVS Stock Data

1.18B
22.01M
6.05%
83.23%
0.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Leiden

About PHVS

pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.